Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy

Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant mutations to arise in the protease, particularly in patients receiving indinavir or ritonavir treatment, is...

Popoln opis

Bibliografske podrobnosti

izdano v:	J Virol
Principais autores:	Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Format:	Artigo
Jezik:	Inglês
Izdano:	American Society for Microbiology (ASM) 2003
Teme:	Vaccines and Antiviral Agents
Online dostop:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC140781/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12502847/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/JVI.77.2.1306-1315.2003
Oznake:	Označite Brez oznak, prvi označite!